Skip to content

B7981027 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515438-33-00
Acronym
B7981027
Enrollment
68
Registered
2025-10-14
Start date
2026-01-12
Completion date
Unknown
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata

Brief summary

Response based on achieving an absolute SALT score ≤10 at Week 24.

Detailed description

PGI‑C response defined as a score of “moderately improved” or “greatly improved” at Week 24., • Change from baseline (CFB) in SALT score at all visits. • Response based on achieving absolute SALT score ≤10 at all visits (except for that included as the primary endpoint). • Response based on achieving absolute SALT score ≤20 at all visits (except for that included as the primary endpoint)., PGI-C response at all visits (except for that included as a key secondary endpoint)., •Response based on improvement from baseline for each AAPPO Item (11 endpoints). •CFB in AAPPO activity limitation and emotional symptoms scores at all visits. • CFB in PROMIS Parent Proxy Depressive Symptoms T-score at all visits., •CFB in PROMIS Parent Proxy Anxiety Symptoms T-score at all visits. •CFB in BRIEF®2 T-scores for the 3 index scores (Behavior Regulation Index [BRI], Emotional Regulation Index [ERI], Cognitive Regulation Index [CRI]) at all visits. •CFB in modified CDLQI total score at all visits., • Response based on achieving at least 2 grade improvement or a score of 3 in EBA score at all visits in participants with an abnormal EBA at baseline., Response based on achieving at least 2 grade improvement or a score of 3 in ELA score at all visits in participants with an abnormal ELA at baseline., Plasma concentration of ritlecitinib at 1 hr (±15 min) and 3 hr (±30 min) post-dose at Week 4 or Week 8., •Incidence of treatment-emergent adverse events (AEs) (including audiological and neurological treatment-emergent AEs). •Incidence of serious AEs (SAEs) and AEs leading to permanent discontinuation from the study., Acceptability and palatability assessment.

Interventions

Sponsors

Pfizer Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Response based on achieving an absolute SALT score ≤10 at Week 24.

Secondary

MeasureTime frame
PGI‑C response defined as a score of “moderately improved” or “greatly improved” at Week 24., • Change from baseline (CFB) in SALT score at all visits. • Response based on achieving absolute SALT score ≤10 at all visits (except for that included as the primary endpoint). • Response based on achieving absolute SALT score ≤20 at all visits (except for that included as the primary endpoint)., PGI-C response at all visits (except for that included as a key secondary endpoint)., •Response based on improvement from baseline for each AAPPO Item (11 endpoints). •CFB in AAPPO activity limitation and emotional symptoms scores at all visits. • CFB in PROMIS Parent Proxy Depressive Symptoms T-score at all visits., •CFB in PROMIS Parent Proxy Anxiety Symptoms T-score at all visits. •CFB in BRIEF®2 T-scores for the 3 index scores (Behavior Regulation Index [BRI], Emotional Regulation Index [ERI], Cognitive Regulation Index [CRI]) at all visits. •CFB in modified CDLQI total score at all visits., • R

Countries

Czechia, France, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026